Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Molecular Mechanism Identified That Enables Leukemia Cells to Evade Chemotherapy

By LabMedica International staff writers
Posted on 01 Feb 2012
Cancer researchers have identified a molecular mechanism used by acute myeloid leukemia (AML) cells to evade chemotherapy.

Investigators at the University of Colorado School of Medicine (Denver, USA) used novel molecular and computational approaches to perform genome-wide short-hairpin RNA screens to identify proteins that mediate the fate of AML cells after exposure to the drug cytarabine (cytosine arabinoside). More...
Gene expression profiling of AML cells exposed to cytarabine was carried out to identify genes with expression induced by the drug treatment. Such gene activity was compared to records of gene expression data from primary patient samples.

Results published in the January 13, 2012, online edition of the journal Leukemia strongly implicated cell-cycle checkpoint proteins, particularly WEE1, as critical mediators of AML cell survival after cytarabine exposure. Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival. Pharmacologic inhibition of WEE1 in AML cell lines and primary cells increased the potency of cytarabine.

Wee1 inhibits entry of cells into mitosis, and its absence leads to division at a premature stage and sub-normal cell size. Conversely, when Wee1 expression is increased, mitosis is delayed and cells grow to a large size before dividing. Further experiments conducted as part of the current study demonstrated that inhibition of WEE1 prevented S-phase arrest in AML cells induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically.

“Introducing chemotherapy to cells is like putting a curve in front of a speeding car,” said first author Dr. Christopher Porter, assistant professor of pediatrics at the University of Colorado School of Medicine. “Cells that can put on the brakes make it around the corner and cells that cannot speed off the track. WEE1 is the brakes. With chemotherapy, we introduce DNA damage in cancer cells – we push them toward the curve hopefully at a greater rate than healthy cells. If WEE1 is there, cancer cells can round the curve. Without it, they flip.”

“I am optimistic that this will eventually lead to a therapeutic regimen that allows us to target AML cells that have escaped conventional therapies,” said Dr. Porter. “In light of
these data, we are already early in the clinical trial planning process.”

Related Links:

University of Colorado School of Medicine



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.